Ayşe Elif Anil Yağcioğlu

Ayşe Elif Anil Yağcioğlu

Auto-generated profile, based on publicly available information

Ayşe Elif Anil Yağcioğlu

Department of Psychiatry, Faculty of Medicine, Hacettepe University, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
JLJose de Leon
Jose de Leon
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
RSRobert L. Smith
Robert L. Smith
EMEspen Molden
Espen Molden
ASAnssi Solismaa
Anssi Solismaa
DMDaniel Mueller
Daniel Mueller
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

15 January 2005 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
AYA. Elif Anil Yagcioglu
A. Elif Anil Yagcioglu
BABerna B. Kivircik Akdede
Berna B. Kivircik Akdede
TTTolga I. Turgut
Tolga I. Turgut
MTMevhibe Tümüklü
Mevhibe Tümüklü
MYM. Kâzim Yazici
M. Kâzim Yazici
HMHerbert Y. Meltzer
Herbert Y. Meltzer
Several open trials and case studies have reported beneficial effects following the addition of risperidone for partial responders to clozapine. The purpose of this study was to carry out a placebo-controlled, randomized, double-blind trial of the efficacy, safety, and tolerability of adjunctive treatment with risperidone in patients with schizophrenia partially responsive to clozapine. In this 6-week double-blind study, 30 patients with DSM-IV schizophrenia who had partial response to clozapine despite being treated for a mean of 32 months were randomly assigned to risperidone (N = 16) up to 6 mg/day or placebo (N = 14). Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale, the Clinical Global Impressions-Severity of Illness scale, the Global Assessment of Functioning scale, and the Quality of Life Scale. A variety of safety and tolerability measures were also obtained. Data were collected between November 2001 and July 2003. Significant improvement was noted in both groups on a variety of measures of psychopathology, but there was significantly greater improvement in the placebo-treated patients on the primary outcome measure, the PANSS positive symptom subscale. There were no significant differences between the treatment groups regarding extrapyramidal symptoms, weight gain, vital signs, serum clozapine levels, and QTc interval. The only side effect significantly more severe in risperidone-treated compared to placebo-treated patients was sedation. The patients treated with risperidone developed significant increases in plasma prolactin levels. Adjunctive risperidone treatment in schizophrenia patients partially responsive to clozapine does not significantly improve psychopathology or quality of life compared to placebo in a 6-week period.

15 February 2008 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
HMHerbert Y. Meltzer
Herbert Y. Meltzer
WBWilliam V. Bobo
William V. Bobo
ARAjanta Roy
Ajanta Roy
KJKaru Jayathilake
Karu Jayathilake
CAChen Aygun
Chen Aygun
JSJoyce G. Small
Joyce G. Small
Clozapine, despite its side-effect burden, has been considered to be the drug of choice for patients with schizophrenia whose psychotic symptoms fail to respond adequately to other anti-psychotic drugs. There are conflicting data concerning the potential utility of olanzapine in treatment-resistant schizophrenia at doses beyond the 10- to 20-mg/day range that has proven to be effective for most nonrefractory patients with schizophrenia. The main objective of this study was to compare the efficacy and tolerability of high-dose olanzapine (target dose, 25-45 mg/day) and clozapine (300-900 mg/day) in patients with schizophrenia or schizoaffective disorder who had failed to respond adequately to prior treatment with other antipsychotic drugs. This 6-month, randomized, double-blind, parallel-group study compared the efficacy and tolerability of olanzapine (mean dose, 34 mg/day; N = 19) or clozapine (mean dose, 564 mg/day; N = 21) in patients with treatment-resistant schizophrenia or schizoaffective disorder, diagnosed according to DSM-IV criteria. Outcome measures included psychopathology, cognitive performance (as assessed with a comprehensive neuropsychological test battery), and tolerability. The study was conducted between May 2000 and December 2003. Robust and significant (mostly p < .001) improvement in multiple measures of psychopathology, mainly between 6 weeks and 6 months of treatment, was found in both treatment groups, with no significant difference between the 2 treatments except for the Global Assessment of Functioning score, which favored clozapine (p = .01). Improvement in some domains of cognition was significant-and equivalent for both drugs, as well. Nonsignificantly different improvement in Verbal List Learning-Immediate Recall (p < .05), Controlled Word Association Test (p < .05), and Digit Symbol Substitution Test (p < .001) was found. There were no significant differences in extrapyramidal symptoms. Weight gain was significantly (p = .01) greater with olanzapine. Olanzapine, at higher than customary doses, demonstrated similar efficacy to clozapine in treatment-resistant schizophrenia and schizoaffective disorder in this study. However, the small sample size precludes definitively concluding that the 2 treatments are equivalent, at these doses, in treatment-resistant schizophrenia. The metabolic side effects of olanzapine are a limitation in its use. ClinicalTrials.gov identifier NCT00179231.

1 January 1999 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
TSTomiki Sumiyoshi
Tomiki Sumiyoshi
AAA. Elif Anil
A. Elif Anil
DJDai Jin
Dai Jin
KJKaru Jayathilake
Karu Jayathilake
MLMyung Lee
Myung Lee
HMHerbert Y. Meltzer
Herbert Y. Meltzer
Previous studies have suggested decreased N-methyl-d-aspartate (NMDA)-type glutamate receptor function may contribute to increased negative symptoms

1 March 1996 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
AKA. E. Kostakolu
A. E. Kostakolu
KYK. M. Yazici
K. M. Yazici
TET. Erbas
T. Erbas
NGN. Güvener
N. Güvener

24 March 2005 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
AEAygun Ertugrul
Aygun Ertugrul
AYA. Elif Anil Yagcioglu
A. Elif Anil Yagcioglu
NENurhayat Eni
Nurhayat Eni
KYKâzim M. Yazici
Kâzim M. Yazici
Abstract  The aim of the present study was to assess the occurence of obsessive‐compulsive symptoms (OCS) in schizophrenic patients treated with clozapine, and to examine the relationship between OCS and other clinical variables. The results support earlier findings which suggest that clozapine produces or unmasks OCS. In addition, the severity of OCS was not related to other dimensions of psychopathology, severity of illness, clinical improvement or dose and duration of clozapine treatment.